421 related articles for article (PubMed ID: 8400114)
1. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Szalkowski DM; MacIntyre DE; Bach TJ; Luell S; Meuer R; Sahoo SP; Alberts AW; Chabala JC
J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Alberts AW; Bugianesi RL; Chabala JC; Ponpipom MM
J Pharmacol Exp Ther; 1988 Aug; 246(2):534-41. PubMed ID: 2841449
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
[TBL] [Abstract][Full Text] [Related]
4. Functional validation of platelet-activating factor receptor sites characterized biochemically by a specific and reproducible [3H]platelet-activating factor binding in human platelets.
Tahraoui L; Floch A; Cavero I
J Pharmacol Exp Ther; 1990 Mar; 252(3):1221-7. PubMed ID: 2156995
[TBL] [Abstract][Full Text] [Related]
5. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation.
Tahraoui L; Floch A; Mondot S; Cavero I
Mol Pharmacol; 1988 Aug; 34(2):145-51. PubMed ID: 2842653
[TBL] [Abstract][Full Text] [Related]
6. Yangambin: a new naturally-occurring platelet-activating factor receptor antagonist: binding and in vitro functional studies.
Castro-Faria-Neto HC; Bozza PT; Cruz HN; Silva CL; Violante FA; Barbosa-Filho JM; Thomas G; Martins MA; Tibiriçá EV; Noel F
Planta Med; 1995 Apr; 61(2):101-5. PubMed ID: 7753913
[TBL] [Abstract][Full Text] [Related]
7. Characterization of platelet-activating factor (PAF) receptor by specific binding of [3H]L-659,989, a PAF receptor antagonist, to rabbit platelet membranes: possible multiple conformational states of a single type of PAF receptors.
Hwang SB; Lam MH; Hsu AH
Mol Pharmacol; 1989 Jan; 35(1):48-58. PubMed ID: 2536468
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
[TBL] [Abstract][Full Text] [Related]
9. Effect of SR 27417 on the binding of [3H]PAF to rabbit and human platelets and human polymorphonuclear leukocytes.
Herbert JM; Laplace MC; Cailleau C; Maffrand JP
J Lipid Mediat; 1993 May; 7(1):57-78. PubMed ID: 8395255
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
Tsunoda H; Sakuma Y; Harada K; Muramoto K; Katayama S; Horie T; Shimomura N; Clark R; Miyazawa S; Okano K
Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331
[TBL] [Abstract][Full Text] [Related]
11. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies.
Ortega MP; García MC; Gijón MA; de Casa-Juana MF; Priego JG; Sanchez Crespo M; Sunkel C
J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
Crowley HJ; Yaremko B; Selig WM; Janero DR; Burghardt C; Welton AF; O'Donnell M
J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
Ring PC; Seldon PM; Barnes PJ; Giembycz MA
Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding.
Herbert JM; Laplace MC; Maffrand JP
J Lipid Mediat; 1992 Feb; 5(1):1-12. PubMed ID: 1327264
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
Parry MJ; Alabaster VA; Cheeseman HE; Cooper K; deSouza RN; Keir RF
J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676
[TBL] [Abstract][Full Text] [Related]
16. [3H]52770 RP, a platelet-activating factor receptor antagonist, and tritiated platelet-activating factor label a common specific binding site in human polymorphonuclear leukocytes.
Marquis O; Robaut C; Cavero I
J Pharmacol Exp Ther; 1988 Feb; 244(2):709-15. PubMed ID: 2831350
[TBL] [Abstract][Full Text] [Related]
17. The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes.
Floch A; Tahraoui L; Sedivy P; Cavero I
J Pharmacol Exp Ther; 1991 Aug; 258(2):567-75. PubMed ID: 1650834
[TBL] [Abstract][Full Text] [Related]
18. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
[TBL] [Abstract][Full Text] [Related]
19. Evidence for the existence and ionic modulation of platelet-activating factor receptors mediating degranulatory responses in human polymorphonuclear leukocytes.
Marquis O; Robaut C; Cavero I
J Pharmacol Exp Ther; 1989 Jul; 250(1):293-300. PubMed ID: 2545861
[TBL] [Abstract][Full Text] [Related]
20. (+/-)-trans-2-(3-Methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5- trimethoxyphenyl)tetrahydrofuran (L-659,989), a novel, potent PAF receptor antagonist.
Ponpipom MM; Hwang SB; Doebber TW; Acton JJ; Alberts AW; Biftu T; Brooker DR; Bugianesi RL; Chabala JC; Gamble NL
Biochem Biophys Res Commun; 1988 Feb; 150(3):1213-20. PubMed ID: 2829894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]